FDA, companies add 3 heartburn meds to recall amid cancer concerns

At least three antacids were added this week to a growing recall of the products due to potential cancer-causing contamination, multiple media outlets reported.

According to CNN, both Denton Pharma Inc. and Appco Pharma LLC recalled multiple batches of ranitidine tablets and ranitidine hydrochloride capsules due to the detection of a potentially carcinogenic impurity known as N-Nitrosodimethylamine, or NDMA.

The Denton recall affects unexpired lots of 150 mg and 300 mg ranitidine tablets, while the Appco action affects 150 mg and 300 mg batches of its ranitidine hydrochloride capsules, the network reported.

Meanwhile, Mylan Pharmaceuticals issued a voluntary recall of three lots of Nizatidine capsules, known more commonly as Axid, on the same contamination fears, KAIT reported.

According to the FDA, the Mylan products were distributed nationwide to wholesalers, mail order and retail pharmacies as well as a distributor between June 2017 and August 2018.

None of the companies involved in these most recent recalls have received any reports of adverse effects from the drugs, the FDA confirmed.